Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 17, 2026, 7:56 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 17,839 matching trials from the live ClinicalTrials.gov search.
Conditions
Juvenile Idiopathic Arthritis
Interventions
CP-690,550
Drug
Lead sponsor
Pfizer
Industry
Eligibility
2 Years to 17 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
4
States / cities
Minneapolis, Minnesota • Cincinnati, Ohio • Portland, Oregon
Conditions
Anaplastic Astrocytoma, IDH-Wildtype, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, Diffuse Astrocytoma, IDH-Wildtype, Glioblastoma, Oligoastrocytoma, Oligodendroglioma, WHO Grade II Glioma, WHO Grade III Glioma
Interventions
Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy, Temozolomide
Other · Radiation · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Houston, Texas
Conditions
Lung Cancer, Head and Neck Cancer, Hearing Loss, Ototoxicity, Tinnitus, Neuropathy
Interventions
SPI-1005 Low Dose, SPI-1005 Middle Dose, SPI-1005 High Dose, Placebo
Drug
Lead sponsor
Sound Pharmaceuticals, Incorporated
Industry
Eligibility
19 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Non-Alcoholic Steatohepatitis(NASH)
Interventions
Active treatment, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
3
States / cities
Anaheim, California • Durham, North Carolina
Conditions
Uterine Cervical Neoplasms
Interventions
Pembrolizumab, Placebo for pembrolizumab, Cisplatin, External Beam Radiotherapy (EBRT), Brachytherapy
Biological · Drug · Radiation
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,060 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
28
States / cities
Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 25 more
Conditions
Osteoporosis, Spinal Cord Injury
Interventions
Denosumab, Placebo (identical Denosumab volume of normal saline)
Drug
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
2
States / cities
West Orange, New Jersey • The Bronx, New York
Completed Phase 3 Interventional Accepts healthy volunteers Results available

To Compare SH T00658ID Over Ortho Tri-Cyclen Lo (US/Canada)

NCT00754065
Conditions
Contraception
Interventions
Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027), Ortho Tri Cyclen Lo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
409 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
34
States / cities
Independence, Arizona • Phoenix, Arizona • Encinitas, California + 29 more
Completed Phase 2Phase 3 Interventional Results available

Trial of CF101 to Treat Patients With Psoriasis

NCT01265667
Conditions
Plaque Psoriasis
Interventions
CF101, Placebo
Drug
Lead sponsor
Can-Fite BioPharma
Industry
Eligibility
18 Years to 80 Years
Enrollment
293 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
New York, New York
Conditions
Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer, Small Cell Carcinoma, Sclc, SCLC,Extensive Stage, Lung Cancer, Lung Cancer Metastatic, Lung Cancer Stage IV
Interventions
BL-M14D1 and Atezolizumab, Carboplatin+ Etoposide + Atezolizumab followed by Atezolizumab and Lurbinectedin
Drug
Lead sponsor
SystImmune Inc.
Industry
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
7
States / cities
Springdale, Arkansas • Glendale, California • Long Beach, California + 4 more
Conditions
MPS IIIA, Sanfilippo Syndrome, Sanfilippo A, Mucopolysaccharidosis III
Interventions
ABO-102
Drug
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
2 Years to 18 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia
Interventions
ASTX727, Dacogen
Drug
Lead sponsor
Astex Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
39
States / cities
Anniston, Alabama • Phoenix, Arizona • Tucson, Arizona + 32 more
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
sorafenib tosylate, tanespimycin, laboratory biomarker analysis, pharmacological study, magnetic resonance imaging
Drug · Other · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Detroit, Michigan
Completed Early Phase 1 Interventional Accepts healthy volunteers

Metabolic Causes of Thrombosis in Type 2 Diabetes Mellitus

NCT00829699
Conditions
Type 2 Diabetes
Interventions
euinsulinemic euglycemic glucose clamp, euinsulinemic hyperglycemic glucose clamp, Hyperinsulinemic euglycemic glucose clamp, Hyperinsulinemic hyperglycemic glucose clamp
Procedure
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 60 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Completed Phase 1 Interventional Accepts healthy volunteers

Thorough QT Study to Evaluate Ampreloxetine in Healthy Subjects

NCT04688632
Conditions
Symptomatic Neurogenic Orthostatic Hypertension, nOH
Interventions
Ampreloxetine <Dose A>, Ampreloxetine <Dose B>, Ampreloxetine Placebo, Moxifloxacin, Moxifloxacin Placebo
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
18 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Tempe, Arizona
Conditions
Renal Cancer
Interventions
mannitol, placebo
Drug · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
New York, New York
Conditions
Renal Function, Liver Transplant
Interventions
Introduction of everolimus with reduced cyclosporine or tacrolimus dose, the earliest 1 month and the latest 6 months after liver transplantation.
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
1 Month to 17 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
9
States / cities
Los Angeles, California • New Haven, Connecticut • Chicago, Illinois + 6 more
Conditions
Leukemia, Myeloid, Acute
Interventions
Fludarabine, Cyclophosphamide, Leukapheresis, Cytokine-induced killer cells, IL-2, ALT-803, Peripheral blood for correlative studies, Bone marrow for correlative studies
Drug · Procedure · Biological
Lead sponsor
Washington University School of Medicine
Other
Eligibility
2 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Completed Not applicable Interventional Accepts healthy volunteers Results available

Text Reminders to Immunize in a Managed Care Organization

NCT01806714
Conditions
Human Papilloma Virus
Interventions
Text-based reminder for recommended HPV vaccine or WCC, Non-specific text-based reminder (general health tip)
Other
Lead sponsor
University of Rochester
Other
Eligibility
11 Years to 18 Years
Enrollment
3,812 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Rochester, New York
Conditions
Atopic Dermatitis, Moderate-to-severe Atopic Dermatitis
Interventions
Rocatinlimab, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 54 Years
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
72
States / cities
Scottsdale, Arizona • Tempe, Arizona • Little Rock, Arkansas + 61 more
Conditions
HIV Infections, Meningitis
Interventions
Quadrivalent meningococcal conjugate vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 24 Years
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
35
States / cities
Alhambra, California • Long Beach, California • Los Angeles, California + 25 more
Conditions
Endometrial Cancer
Interventions
Ixabepilone, Doxorubicin, Paclitaxel
Drug
Lead sponsor
R-Pharm
Industry
Eligibility
18 Years and older · Female only
Enrollment
551 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
28
States / cities
Mobile, Alabama • Englewood, Colorado • New Haven, Connecticut + 25 more
Conditions
Tympanic Membrane Perforation
Interventions
FGF-2, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
New York, New York
Conditions
Obstetric Labour, Premature
Interventions
Retosiban, Atosiban, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
10 Weeks to 20 Weeks
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Park Ridge, Illinois • Galveston, Texas
Conditions
Multiple Myeloma
Interventions
Daratumumab and Recombinant Human Hyaluronidase, Lenalidomide
Drug
Lead sponsor
Eden Biltibo
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Nashville, Tennessee